Search
Search
About
Log in
Join
Experiences with
Immunotherapy
Posts
Communities
1,690 public posts
Filter results
What is MSI?
The acronym "MSI" has come up in a number of posts concerning the use of
immunotherapy
, specifically with pembrolizumab (trade name Keytruda). Never having heard of MSI before I looked it up in the Wikipedia.
The acronym "MSI" has come up in a number of posts concerning the use of
immunotherapy
, specifically with pembrolizumab (trade name Keytruda). Never having heard of MSI before I looked it up in the Wikipedia.
AlanMeyer
in
Advanced Prostate Cancer
3 years ago
cdk12
So I guess my best bet might be
immunotherapy
targeting the CDK12 mutation?
So I guess my best bet might be
immunotherapy
targeting the CDK12 mutation?
spencoid2
in
Advanced Prostate Cancer
3 years ago
Out of Nivolumab/Opdivo Clinical Trial
My husband, Steve (Stevana on this site), is now out of the phase 2 clinical trial for the
immunotherapy
drug Nivolumab (a/k/a Opdivo). He started the trial in August, 2020 which also included infusions of Docetaxel.
My husband, Steve (Stevana on this site), is now out of the phase 2 clinical trial for the
immunotherapy
drug Nivolumab (a/k/a Opdivo). He started the trial in August, 2020 which also included infusions of Docetaxel.
Avanat
in
Advanced Prostate Cancer
3 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Small cell lung cancer
I was told yesterday that
immunotherapy
, should we need further treatment in the future isn’t really beneficial for small cell. Many thanks
I was told yesterday that
immunotherapy
, should we need further treatment in the future isn’t really beneficial for small cell. Many thanks
JPotter42
in
The Roy Castle Lung Cancer Foundation
3 years ago
“I think we’ll cure leukemia in my lifetime”
Our next goal is to increase the survival rate to 90% and eliminate the need for chemotherapy by using a combination of targeted therapy and
immunotherapy
.”
Our next goal is to increase the survival rate to 90% and eliminate the need for chemotherapy by using a combination of targeted therapy and
immunotherapy
.”
Manouche
in
MPN Voice
3 years ago
Scientists discover novel oncogenic driver gene in human lung cancer
Although tyrosine kinase inhibitors and
immunotherapy
have contributed to survival benefits in some patients, the overall survival rates for NSCLCs remain low. Patients with NSCLC that are driven by KRAS mutations are often unresponsive to tyrosine kinase inhibitors and have a poor prognosis.
Although tyrosine kinase inhibitors and
immunotherapy
have contributed to survival benefits in some patients, the overall survival rates for NSCLCs remain low. Patients with NSCLC that are driven by KRAS mutations are often unresponsive to tyrosine kinase inhibitors and have a poor prognosis.
2greys
in
Lung Conditions Community Forum
3 years ago
Early lung cancer co-opts immune cell into helping tumors invade the lungs
By investigating this microenvironment, researchers can find key players that drive tumor growth that can be tested as targets for
immunotherapy
. But modifying macrophages therapeutically has proven difficult.
By investigating this microenvironment, researchers can find key players that drive tumor growth that can be tested as targets for
immunotherapy
. But modifying macrophages therapeutically has proven difficult.
2greys
in
Lung Conditions Community Forum
3 years ago
Moffitt Researchers Develop Non-invasive Approach to Measure Biomarker Levels, Predict Outcomes in Lung Cancer Patients
In a new article published in the Journal for
ImmunoTherapy
of Cancer, Moffitt Cancer Center researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient’s response to therapy
In a new article published in the Journal for
ImmunoTherapy
of Cancer, Moffitt Cancer Center researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient’s response to therapy
2greys
in
Lung Conditions Community Forum
3 years ago
Update on AMG 509 immunotherapy
I have been communicating regularly with an
immunotherapy
bro. His PSA has dropped from 87 to 4 and he had scans last week. He reviewed them with our mutual oncologist this morning and received spectacularly good news. Tumors have regressed!!
I have been communicating regularly with an
immunotherapy
bro. His PSA has dropped from 87 to 4 and he had scans last week. He reviewed them with our mutual oncologist this morning and received spectacularly good news. Tumors have regressed!!
Philly13
in
Advanced Prostate Cancer
3 years ago
Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in castration sensitive prostate cancer - ERC -6.15.21
Palvimo and Ville Paakinaho https://erc.bioscientifica.com/view/journals/erc/aop/erc-21-0038/erc-21-0038.xml
[i]Using
in prostate cancer patients: more than sipuleucel-T[/i] - Author(s): Jamie Tae Wook Kwon, Richard J Bryant, and Eileen E Parkes https://erc.bioscientifica.com/view
Palvimo and Ville Paakinaho https://erc.bioscientifica.com/view/journals/erc/aop/erc-21-0038/erc-21-0038.xml
[i]Using
in prostate cancer patients: more than sipuleucel-T[/i] - Author(s): Jamie Tae Wook Kwon, Richard J Bryant, and Eileen E Parkes https://erc.bioscientifica.com/view
cujoe
in
Fight Prostate Cancer
3 years ago
Scientists learn what fuels the 'natural killers' of the immune system
“There’s a lot of interest right now in NK cells as a potential target of
immunotherapy
,” says Joseph Sun, an immunologist in the Sloan Kettering Institute.
“There’s a lot of interest right now in NK cells as a potential target of
immunotherapy
,” says Joseph Sun, an immunologist in the Sloan Kettering Institute.
2greys
in
Lung Conditions Community Forum
3 years ago
Diabetes and immunotherapy
Has anyone been diagnosed with diabetes while having
immunotherapy
?
Has anyone been diagnosed with diabetes while having
immunotherapy
?
Hendon1958
in
Lung Cancer Support
3 years ago
ASCO presentations on melanoma research this week
The researchers found that the
immunotherapy
combination doubled the amount of time that the melanoma was stopped compared with giving nivolumab alone.
The researchers found that the
immunotherapy
combination doubled the amount of time that the melanoma was stopped compared with giving nivolumab alone.
missyrand
Ambassador
in
Melanoma Caregivers
3 years ago
Back at it again
Trial selinexor but my doctor thinks I got the drug due to my nausea Only two other things I did was break my collar bone three weeks ago and get my second Covid shot in April Biopsy today but let’s face it it cancer again but must follow protocol I guess I am out of the study Looking at either
immunotherapy
Trial selinexor but my doctor thinks I got the drug due to my nausea Only two other things I did was break my collar bone three weeks ago and get my second Covid shot in April Biopsy today but let’s face it it cancer again but must follow protocol I guess I am out of the study Looking at either
immunotherapy
Supermary
in
My Ovacome
3 years ago
Akkermansia
Remarkably, Akk has also been reported to impact cancer
immunotherapy
." -Patrick [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515896/ [2] https://pubmed.ncbi.nlm.nih.gov/29988102/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068512/
Remarkably, Akk has also been reported to impact cancer
immunotherapy
." -Patrick [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515896/ [2] https://pubmed.ncbi.nlm.nih.gov/29988102/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068512/
pjoshea13
in
Advanced Prostate Cancer
3 years ago
No intensification - is doc too laid back?
I can understand this in terms of
immunotherapy
like PD-1 and PD-L1 checkpoint inhibitors, which apparently require a higher mutational burden than my 4 Muts/Mb to have an effect (although my thinking was "why not try immuno anyway better safe than sorry").
I can understand this in terms of
immunotherapy
like PD-1 and PD-L1 checkpoint inhibitors, which apparently require a higher mutational burden than my 4 Muts/Mb to have an effect (although my thinking was "why not try immuno anyway better safe than sorry").
Purple-Bike
in
Advanced Prostate Cancer
3 years ago
Lynparza
I’m thinking the doctors thinking
immunotherapy
next. If that doesn’t work I don’t know where to turn to next I am so devastated. Help guys please!!! 💔💔💔😭😭😭. Could really use some advice.
I’m thinking the doctors thinking
immunotherapy
next. If that doesn’t work I don’t know where to turn to next I am so devastated. Help guys please!!! 💔💔💔😭😭😭. Could really use some advice.
Fight11
in
Advanced Prostate Cancer
3 years ago
Just to introduce myself
As only palliative care was offered, we read very widely (we are still reading and won't ever stop) and have had inter tumorial
immunotherapy
and cryo ablation with Dr Jason R Williams in Mexico. We are taking lots of supplements, COC drugs (no Doxy as it's an antibiotic) and RSO.
As only palliative care was offered, we read very widely (we are still reading and won't ever stop) and have had inter tumorial
immunotherapy
and cryo ablation with Dr Jason R Williams in Mexico. We are taking lots of supplements, COC drugs (no Doxy as it's an antibiotic) and RSO.
Winner123
in
SHARE Metastatic Breast Cancer
3 years ago
Immunotherapy Clinical Trial or Olaparib (Lynparza)?
We've been offered two options: 1. a trial of atezolizumab + cabozantinib - an
immunotherapy
treatment that seems to be promising in Breast Cancer. But, if he is put into the control group, he'd receive enzalutamide (another ADT drug). 2.
We've been offered two options: 1. a trial of atezolizumab + cabozantinib - an
immunotherapy
treatment that seems to be promising in Breast Cancer. But, if he is put into the control group, he'd receive enzalutamide (another ADT drug). 2.
PCdaughte
in
Advanced Prostate Cancer
3 years ago
Continuing discussion of Adaptive Theory-- Why does early chemotherapy result in lower response rates to Lu-177 and immunotherapy??
In the CHECKMATE 650 trial (
Immunotherapy
), people that were chemo naive had a 25% response rate to Opdivo and Yervoy versus only a 10% response rate by those having previous chemo.
In the CHECKMATE 650 trial (
Immunotherapy
), people that were chemo naive had a 25% response rate to Opdivo and Yervoy versus only a 10% response rate by those having previous chemo.
NPfisherman
in
Fight Prostate Cancer
3 years ago
1
...
29
30
31
...
85
Next page
10
20
30
40
50
60
70
80
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
476 results
The Roy Castle Lung Cancer Foundation
244 results
CLL Support
142 results
View top 10 communities
Sort by
Most Relevant
Newest